Take a look at the 5 yr chart and know that Biotime will have two HUGE products on the market within 6 months. A)Best in class cancer diagnostics product PanC-DX, and B) cosmetic surgery product Renevia.
Both of these products are cutting edge and industry game changers. Also both products are partnered with top institutions/hospitals; Weill Cornell for PanC-DX and for Renevis the Spain Stem Cell Center which is one of largest cosmetic surgery center in EU.
Game changers because they are next generation, meaning that they will REPLACE the current methods of practice. PanC-DX will be a simple blood test and will be crossed checked with the latest genetic markers replacing radioactive mammograms that are often a shot in the dark in terms of detecting malignant early formations. And Biotimes cosmetic surgery product Renevia will use an extra-cellular matrix along with a patients own adipose(fat) stem cells replacing the use of silicone.
Dr West is a true pioneer, medical app's are the future of healthcare. LifeMPs will might make a tremendous IPO in a year or two!
Crossing my fingers, but then again feel secure knowing two of the leading scientists in this field are on the same page!
For those not following trends within the industry.....over the last year the race to reprogram the stem cell has moved from IPS cell to SCNT(therapeutic cloning). Most scientists now know that reprogramming autologous(IPS cells) is more complicated then once thought. No magic bullet, and will instead take years to perfect as scientists dig deeper and deeper into such complexities.
The 'cloning' .....and for that matter embryonic stem cell stigma of the past is fading and the urgency of finding cures to disease has superceded the fears of such technologies. Recently Dr. West of Biotime hit the nail on the head when he compared the fear of hESC's to Harvard's ban of recombinant DNA in the 1970's.
Robert Lanza's patents over the last 3 years reflect this trend in the scientific community and it's refocus on therapeutic cloning. Although not perfected the SCNT method looks to be the simplest way to perfect reprogramming hESC's into histocompatible cells/tissues for transplant.
Here are 5 of Lanza's SCNT patents over the last few years:
-11/07/13 - 20130295056 - Generation of histocompatible tissues using nuclear transplantation
-08/02/12 - 20120196769 - Methods of repairing tandemly repeated dna sequences and extending cell life-span using nuclear transfer
-09/27/12 - 20120246746 - Method for generating immune-compatible cells and tissues using nuclear transfer techniques
-07/19/12 - 20120184035 - Methods and compositions for reprogramming cells
-11/03/11 - 20110268709 - Generation of histocompatible tissues using nuclear transplantation
Happy Independence Day!
And to add...yes LP can sell at any time, but the point is they took a 30 ML dollar chance. Yes short term upside is predictable here but also med and long term looking better after ACTC settled lawsuit and finally hiring a CEO.
Now three years later Biotime's Panc-DX is poised to be the worlds best in class product. Quick & cheap this cancer detection product will use a patients blood sample and be so sensitive it will redefine the way cancer is defined. At what point do cancer cells start to multiply and at what point do these growing cells take on the definition of cancer.
Biotimes Panc-DX uses the deepest set of gene markers and nano technology which will make it the choice for not only detecting cancer but also predicting multiple types of cancer before actually forming.Pre-cancer detections will now be possible giving the patient more time to prepare for a method of both treatment and PREVENTION.
A true break though that will send ripples through the medical world. Look for major announcements for it's EU release by years end.
Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States. In 2011–2012, Mount Sinai Hospital was ranked as one of America's best hospitals by U.S. News & World Report in 12 specialties, and in 2013 Expertscape recognized it as having the world's highest level of expertise in three programs.   
Trials will be short and positive. This is not a long drawn out drug trial, more like testing a patients blood to see cancer gene expression using cutting edge database/nano particle ip.
Three years in the making with WeillCornell:
BioTime Licenses Weill Cornell-Developed Vascular Cells Technology; Anti-Cancer Tumor Potential
Sept 2011-BioTime, Inc. announced today it has entered into an exclusive agreement with Cornell University for the worldwide development and commercialization of technology developed at Weill Cornell Medical College for the differentiation of human embryonic stem cells into vascular endothelial cells. Potential uses of this technology may include a new modality for targeting cancer tumors.
Vascular endothelial cells form the blood vessels that support the growth of cancerous tumors. The technology may be used to derive vascular endothelial cells engineered to “deliver a toxic payload to the developing blood vessels of a tumor to remove malignant tumors while not affecting nearby normal tissues.”
Forgot to mention another partner...Stem Center, Palma de Mallocra, Spain for
adipose reconstructive surgery using Biotimes regen therapeutic device Renevia.
The 600+ patents are attracting many partners, Wistar cancer Institute(lung cancer diagnostics),
TEVA for AMD, Cornell Weill hospital/University(cancer therapeutics), Appistry inc for medical database subscription, Cedar Sini for Ehealth app products...and the list keeps growing.
Likely, bio times hydrogels(renevia) have a long history of success in hospitals, universities and biotech companies. Very smart ip acquisition.